{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:21:54Z","timestamp":1775035314678,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["YUWCM-2017-28"],"award-info":[{"award-number":["YUWCM-2017-28"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clml.2019.08.009","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T02:08:34Z","timestamp":1567044514000},"page":"735-743.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Hee Yeon","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hwa","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin Young","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyebin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Taek","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Yong","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.08.009_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.009_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.08.009_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.009_bib4","doi-asserted-by":"crossref","first-page":"7531472","DOI":"10.1155\/2016\/7531472","article-title":"The Hasford score may predict molecular response in chronic myeloid leukemia patients: a single institution experience","volume":"2016","author":"Dybko","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.clml.2019.08.009_bib5","first-page":"2485","article-title":"Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy","volume":"8","author":"Xia","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2019.08.009_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","article-title":"Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib","volume":"32","author":"Francis","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2019.08.009_bib7","first-page":"743","article-title":"[Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia]","volume":"35","author":"Feng","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2019.08.009_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clml.2019.08.009_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1345\/aph.1A226","article-title":"Geriatric drug therapy and healthcare utilization in the United Kingdom","volume":"36","author":"Kennerfalk","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clml.2019.08.009_bib10","first-page":"11","article-title":"[Prescription drugs and the elderly: results of the Argento study]","volume":"62","author":"Pizzuti","year":"2006","journal-title":"Ig Sanita Pubbl"},{"key":"10.1016\/j.clml.2019.08.009_bib11","first-page":"1693","article-title":"[Adverse drug reactions in the elderly]","volume":"189","author":"Doucet","year":"2005","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.clml.2019.08.009_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","article-title":"Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data","volume":"84","author":"Breccia","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.08.009_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.009_bib14","series-title":"Final Report of Academic Research Project. The Effect of National Health Examination Program on the Early Diagnosis of Diseases, Medical Utilization, and Health Outcome","year":"2011"},{"key":"10.1016\/j.clml.2019.08.009_bib15","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.009_bib16","series-title":"Life tables","year":"2018"},{"key":"10.1016\/j.clml.2019.08.009_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","article-title":"Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival","volume":"38","author":"Breccia","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.08.009_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neo.2016.07.005","article-title":"Frontline dasatinib treatment in a \u201creal-life\u201d cohort of patients older than 65 years with chronic myeloid leukemia","volume":"18","author":"Latagliata","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.clml.2019.08.009_bib19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"\u201cReal-life\u201d results of front-line treatment with imatinib in older patients (\u2265 65 years) with newly diagnosed chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.08.009_bib20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.009_bib21","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.08.009_bib22","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/cncr.25071","article-title":"Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and\/or renal dysfunction","volume":"116","author":"Tong","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.08.009_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","article-title":"Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction","volume":"16","author":"Sasaki","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.08.009_bib24","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs. imatinib in patients with newly diagnosed Philadelphia chromosome\u2013positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.009_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.009_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.08.009_bib27","doi-asserted-by":"crossref","first-page":"e2014037","DOI":"10.4084\/mjhid.2014.037","article-title":"Chronic myelogenous leukemia (CML) in the elderly","volume":"6","author":"Balducci","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2019.08.009_bib28","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.009_bib29","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.009_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","article-title":"Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"150","author":"Santos","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.08.009_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-007-0326-2","article-title":"Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission","volume":"86","author":"Carella","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.08.009_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-008-0589-2","article-title":"Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients","volume":"88","author":"Kobayashi","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.08.009_bib33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.08.009_bib34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.009_bib35","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.28106","article-title":"Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis","volume":"119","author":"Brunner","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.08.009_bib36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5045\/br.2015.50.4.204","article-title":"Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012","volume":"50","author":"Park","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.clml.2019.08.009_bib37","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.08.009_bib38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"Roy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.009_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clml.2016.06.010","article-title":"Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors","volume":"16","author":"Yin","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.08.009_bib40","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.009_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:44Z","timestamp":1761870824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019313795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2152265019313795"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}